These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27899234)

  • 1. In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine.
    Ferré S; Earley C; Gulyani S; Garcia-Borreguero D
    Sleep Med; 2017 Mar; 31():86-92. PubMed ID: 27899234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.
    Wanner V; Garcia Malo C; Romero S; Cano-Pumarega I; García-Borreguero D
    Adv Pharmacol; 2019; 84():187-205. PubMed ID: 31229171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
    Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
    Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New concepts in the management of restless legs syndrome.
    Garcia-Borreguero D; Cano-Pumarega I
    BMJ; 2017 Feb; 356():j104. PubMed ID: 28242627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Treatment of Restless Legs Syndrome.
    Lv Q; Wang X; Asakawa T; Wang XP
    Curr Neuropharmacol; 2021; 19(3):372-382. PubMed ID: 33380302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic Augmentation in Restless Legs Syndrome/Willis-Ekbom Disease: Identification and Management.
    García-Borreguero D
    Sleep Med Clin; 2015 Sep; 10(3):287-92, xiii. PubMed ID: 26329438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiopathic restless legs syndrome treatment: Progress and pitfalls?
    Ghorayeb I
    Adv Pharmacol; 2019; 84():207-235. PubMed ID: 31229172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome.
    Quiroz C; Gulyani S; Ruiqian W; Bonaventura J; Cutler R; Pearson V; Allen RP; Earley CJ; Mattson MP; Ferré S
    Neuropharmacology; 2016 Dec; 111():160-168. PubMed ID: 27600688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
    García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
    Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatments of augmentation in restless legs syndrome patients.
    Trenkwalder C; Paulus W
    Adv Pharmacol; 2019; 84():255-265. PubMed ID: 31229175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
    Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
    Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurochemical features of idiopathic restless legs syndrome.
    Jiménez-Jiménez FJ; Alonso-Navarro H; García-Martín E; Agúndez JAG
    Sleep Med Rev; 2019 Jun; 45():70-87. PubMed ID: 30965199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
    Geyer J; Bogan R
    Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic augmentation of restless legs syndrome.
    García-Borreguero D; Williams AM
    Sleep Med Rev; 2010 Oct; 14(5):339-46. PubMed ID: 20219397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restless Legs Syndrome: Challenges to Treatment.
    P LMB; E SSA; Castro-Villacañas A; Garcia-Borreguero D
    Sleep Med Clin; 2021 Jun; 16(2):269-277. PubMed ID: 33985652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the pathophysiology of restless legs syndrome.
    Earley CJ; Allen RP; Beard JL; Connor JR
    J Neurosci Res; 2000 Dec; 62(5):623-8. PubMed ID: 11104500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport.
    Ferré S; Quiroz C; Rea W; Guitart X; García-Borreguero D
    Adv Pharmacol; 2019; 84():3-19. PubMed ID: 31229176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).
    Earley CJ; Connor J; Garcia-Borreguero D; Jenner P; Winkelman J; Zee PC; Allen R
    Sleep Med; 2014 Nov; 15(11):1288-301. PubMed ID: 25201131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of iron in restless legs syndrome.
    Allen RP; Earley CJ
    Mov Disord; 2007; 22 Suppl 18():S440-8. PubMed ID: 17566122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain Iron Deficiency Changes the Stoichiometry of Adenosine Receptor Subtypes in Cortico-Striatal Terminals: Implications for Restless Legs Syndrome.
    Rodrigues MS; Ferreira SG; Quiroz C; Earley CJ; García-Borreguero D; Cunha RA; Ciruela F; Köfalvi A; Ferré S
    Molecules; 2022 Feb; 27(5):. PubMed ID: 35268590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.